Evidence map›Paper›PMID 22588943›Full record

ArticleClinical cardiology2012

Treatment and outcomes of acute coronary syndrome in the cancer population.

Syed Wamique Yusuf, Nicoleta Daraban, Nadia Abbasi, Xiudong Lei, Jean-Bernard Durand, Iyad N Daher

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cardiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 137 citations in OpenAlex.

  1. Trial
  2. Article
  3. Five-year retrospective analysis of invasiveCardiovascular diagnosis and therapy · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Coronary artery disease and cancer: Shared risk factors, pathogenesis, and treatment effects.American heart journal plus : cardiology research and practice · 2026
    Review
  8. Review
  9. Review
  10. Article
  11. Short- and long-term outcomes of patients with active cancer presenting with an acute coronary syndrome.Clinical research in cardiology : official journal of the German Cardiac Society · 2024
    Article
  12. Review
  13. Cancer and arterial thrombosis: therapeutic options.Research and practice in thrombosis and haemostasis · 2024
    Article
  14. What to Do When There Is Something Unexpected?Life (Basel, Switzerland) · 2024
    Article
  15. Review
  16. Article
  17. Review
  18. Cancer and Myocardial Infarction in Women.The American journal of cardiology · 2023
    Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Syed Wamique YusufDepartment of Cardiology, University of Texas MD Anderson Cancer Center, Houston, USA. syusuf@mdanderson.org
Nicoleta Daraban
Nadia Abbasi
Xiudong Lei
Jean-Bernard Durand
Iyad N Daher
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRandomized trials have established the benefit of medical therapy and revascularization in the treatment of acute myocardial infarction (MI). Cancer and cardiovascular disease are the 2 most common diseases worldwide. In clinical practice, cancer patients are frequently afflicted with MI. The benefit of medical and/or revascularization therapy in the cancer population with MI is less well known. HYPOTHESIS: Medical and revascularization therapy reduces mortality in cancer patients with MI.

methodsAfter approval by the institutional review board, we retrospectively reviewed all patients with a discharge diagnosis of acute MI who were admitted to the University of Texas MD Anderson Cancer Center between December 2000 and October 2006 and evaluated the association between cardiac treatments with survival outcomes.

resultsA total of 456 patients with a discharge diagnosis of acute MI were identified and included in the study, of which 386 had non-ST-segment elevation MI (NSTEMI) and 70 had ST-segment elevation MI (STEMI). Compared with patients with NSTEMI, patients who had STEMI were more often prescribed aspirin (66% vs 43%; P = 0.004), β-blockers (61% vs 46%; P = 0.018), and thrombolytic therapy (9% vs 0.3%; P = 0.0001). In the multivariable analysis, aspirin use was associated with a 23% decreased risk of death (hazard ratio [HR]: 0.77, 95% confidence interval [CI]: 0.60-0.98, P = 0.033) and β-blocker use was associated with a 36% decreased risk of death (HR: 0.64, 95% CI: 0.51-0.81, P = 0.0002). Statins (HR: 0.82, P = 0.18) and catheter-based revascularization (HR: 0.57, P = 0.09) did not have an impact on the risk of death. Compared with patients with limited cancer, advanced cancer patients were twice as likely to die (HR: 2.12, 95 CI: 1.47-3.04, P < 0.0001). Previous chemotherapy (P = 0.005) and chest radiotherapy (P = 0.017) were associated with increased 1-year mortality, whereas hyperlipidemia (P = 0.018) was protective.

conclusionsIn this study of cancer patients with MI, medical therapy with aspirin and β-blockers was associated with improved survival. The authors have no funding, financial relationships, or conflicts of interest to disclose.

Indexed as

Myocardial RevascularizationThrombolytic TherapyAcademic Medical CentersAcute Coronary SyndromeAdrenergic beta-AntagonistsAgedAspirinCardiovascular AgentsChi-Square DistributionFemaleHumansKaplan-Meier EstimateMaleMultivariate AnalysisNeoplasmsPlatelet Aggregation InhibitorsAdrenergic beta-AntagonistsAspirinCardiovascular AgentsPlatelet Aggregation Inhibitors

Identifiers

PMID22588943
PMCPMC6652695
OpenAlexW2104811656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.